How not to be an enabler: The implications of Amgen v. Sanofi and Regeneron for antibody claims and beyond

2021 Annual Patent Litigation Webinar Series: How not to be an enabler: The implications of Amgen v. Sanofi and Regeneron for antibody claims and beyond

Earn up to 1.0 Professional CLE for NJ/NY/PA

“How not to be an enabler: The implications of Amgen v. Sanofi and Regeneron for antibody claims and beyond” will focus on the evolution of enablement and written description law in the past twenty years and what the landscape looks like today. The presentation will also take a look at the foreign proceedings related to PCSK9 antibodies and how courts across the world have addressed similar concepts in patent law.

Presenters

Matthew Wolf - Partner, Arnold & Porter Kaye Scholer LLP (Washington, DC) Matt Wolf is co-chair of the firm's Intellectual Property practice group. He is also a member of the Litigation practice group and has been lead trial counsel in some of the most significant cases brought by and against global technology companies. His professional activities focus on patent, trade secret, licensing, and business tort issues, particularly involving medical and biomedical technologies and computer hardware, software, and networking. While much of Mr. Wolf's practice is in federal trial courts throughout the United States, he also has extensive arbitration, appellate, and counseling/diligence experience.[Read More]

Larry Coury – Vice President, Dispute Resolution and Associate General Counsel, Regeneron Pharmaceuticals, Inc. (Tarrytown, NY) [Read More]

Moderator Immac (Casey) Thampoe, Regeneron

Thank You To Our Sponsor

GoToWebinar Note: Once you register, you will receive a GoToWebinar confirmation e-mail with a unique link to join the session. Click "Add to calendar" to ensure you don't miss the webinar.